This segment focuses on the development, manufacturing, and marketing of generic pharmaceutical formulations across various therapeutic areas. Caplin Point leverages its R&D capabilities to create cost-effective alternatives to branded drugs, addressing a wide range of medical needs. The company's product portfolio includes tablets, capsules, injectables, and other dosage forms, catering to diverse patient populations. With a strong emphasis on quality and regulatory compliance, Caplin Point ensures that its generic products meet the highest standards of safety and efficacy. The company's market positioning is driven by its ability to offer affordable medicines without compromising on quality, making it a trusted partner for healthcare providers and patients alike. Future opportunities lie in expanding the product pipeline and entering new markets, further solidifying Caplin Point's position as a leading player in the generics industry.

Caplin Steriles Ltd, a subsidiary of Caplin Point Laboratories, specializes in the development and manufacturing of injectable products. This segment addresses the rapidly growing demand for sterile injectables in regulated markets. The company's state-of-the-art manufacturing facilities and stringent quality control processes ensure the production of high-quality injectables that meet international regulatory standards. Caplin Steriles focuses on developing both simple and complex generic injectables, catering to a wide range of therapeutic areas. The company's R&D efforts are directed towards creating innovative formulations and delivery systems that improve patient outcomes. With a strong focus on regulatory compliance and customer satisfaction, Caplin Steriles is well-positioned to capitalize on the growing market for injectable products. Future opportunities include expanding the product pipeline, entering new markets, and forging strategic partnerships to enhance its market reach.